Trial Profile
Effect of deferasirox in patients with myeloproliferative neoplasms and iron overload
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jul 2019
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 06 Dec 2016 Results (n=41) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 29 Apr 2015 New trial record